Meyka Pro banner
Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. (VRDN) Stock Overview

Explore Viridian Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

VRDN●NASDAQ
HealthcareBiotechnology
$29.96
$1.48(4.71%)
U.S. Market opens in 33h 52m

Viridian Therapeutics, Inc. (VRDN)

Meyka AI Score

Z

Key Financials

Market Cap3.4B
P/E Ratio-7.84
EPS (TTM)$-3.37
ROE-0.70%
Fundamental Analysis

AI Price Forecasts

1 Month$34.50
3 Months$28.01
1 Year Target$26.62

VRDN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Viridian Therapeutics, Inc. (NASDAQ: VRDN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Viridian Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VRDN on the NASDAQ shows an RSI of 64.85, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $26.62 for the NASDAQ listing.

Key metrics behind Viridian Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -7.84 and a market capitalization of 3.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VRDN on the NASDAQ.

Price Performance (NASDAQ: VRDN)

1-Day Change
-4.71%
5-Day Change
-0.93%
1-Month Change
33.57%
3-Month Change
22.29%
6-Month Change
69.94%
Year-to-Date (YTD) Change
-3.73%
1-Year Change
1.66%
3-Year Change
85.05%
5-Year Change
52.70%
All-Time (Max) Change
-98.54%

Contact Information

617 272 4600
221 Crescent Street, Waltham, MA, 02453

Company Facts

2,520 Employees
IPO DateJun 18, 2014
CountryUS
Actively Trading

Frequently Asked Questions